Accuryn vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Accuryn is the hemodynamic monitoring system developed by Retia Medical, providing continuous cardiac output and fluid responsiveness measurement in critical care via a proprietary non-invasive algorithm; received FDA 510(k) clearance;
About
Accuryn is a critical care hemodynamic monitoring system developed by Retia Medical, a medical device company headquartered in Ann Arbor, Michigan. The Accuryn Monitoring System provides continuous, real-time measurement of cardiac output, stroke volume, and fluid responsiveness in critically ill patients — parameters that are essential for guiding hemodynamic management in the intensive care unit (ICU) but historically required invasive pulmonary artery catheter (PAC) placement to measure. Retia Medical's proprietary pulse contour analysis algorithm enables continuous cardiac output monitoring using standard arterial line waveforms already present in most ICU patients, without requiring additional invasive access.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.